ArticleRevista medica del Instituto Mexicano del Seguro Social2026
[Pathophysiology of hypervitaminosis B12: from origin to clinical event. Scoping review].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role that hypervitaminosis B12 may play in the clinical course of various diseases is controversial, in addition to being an overlooked laboratory finding. The objective of this review was to map the literature regarding the pathophysiological mechanisms that explain the increased serum levels of vitamin B12 (vB12) in some adult diseases. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Scoping Review Extension (PRISMA-ScR) checklist guided this scoping review. The search was performed in 2 electronic databases (PubMed and Google Scholar), in Spanish and English, for the years between 2000 and 2024. Twenty studies out of 568 found and screened were included. The main pathophysiological mechanisms that explained the hypervitaminosis B12 were 3: (1) oral or parenteral supplementation of vB12, which can induce the formation of autoantibodies anti-transcobalamin II; (2) serum increase of transcobalamins I, II and III by overproduction or reduction in their clearance; and (3) functional deficiency of the metabolism of transcobalamins. In sum, hypervitaminosis B12 denotes a disorder in the metabolism of vB12, and it could serve as a biomarker of a pathophysiological process with diagnostic and prognostic potential for various diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.